Multidrug resistance may be achieved by the activation of membrane transporters, detoxification, alterations in DNA repair or failure in apoptotic pathways. Recent data have suggested an involvement of mitogenic signalling pathways mediated by Ras and phosphoinositol-3-kinase (PI3K/Akt) in controlling multidrug resistance. Since these pathways are important targets for therapeutic interference, we sought to investigate whether blocking effectors kinases by specific inhibitors would result in a sensitization toward cytotoxic drugs. We found that cotreatment of drug-resistant HT29RDB colon cancer cells with the topoisomerase inhibitor doxorubicin and the PI3K-inhibitor LY294002 resulted in massive apoptosis, while cotreatment with the Mek inhibitors PD98059 or U0126 had no effect. This suggested that the PI3K-pathways controls cell survival and drug resistance in these cells. Besides blocking Akt phosphorylation, the PI3K-inibitor increased the intracellular doxorubicin concentration threefold. LY294002 inhibits drug export in a competitive manner as revealed by measuring drug efflux in the presence and the absence of inhibitor. The efficacy of drug efflux inhibition by LY294002 was similar to that achieved by the MRP1 inhibitors MK571 and genistein. We conclude that the PI3K inhibitor LY294002 may have therapeutic potential when combined with doxorubicin in the treatment of MRP1-mediated drug resistance.
Introduction
The success of cancer chemotherapy is limited by multifactorial resistance mechanisms. Analysis of resistance mechanisms has focussed on membrane transporters belonging to the superfamily of ATP binding cassette proteins, particularly on the MDR1 (P-gp) glycoprotein, the multidrug resistance related proteins MRP1 and MRP2, as well as on the mitoxantrone resistance protein MXR/breast cancer-resistance protein BCRP (Bates et al., 2001) . Other mechanisms of drug resistance involve alterations in the apoptotic response, activation of DNA repair or stimulation of detoxifying systems such as the exocytotic pathway for reducing intracellular drug concentration (Stavrovskaya, 2000; Gottesman, 2002; Gottesman et al., 2002) .
Cellular responses toward cytotoxic drugs are controlled by cross-talk between oncogenic signalling pathways and resistance mechanisms. Components of these pathways have been recognized as critical molecules for targeted therapy. Oncogenic signalling pathways are typically activated by overexpression of tyrosine kinase receptors or by mutational activation of cytoplasmic effector proteins which trigger permanent activation of downstream kinase pathways such as the Mek/MAPK and PI3K/Akt-pathways, promote cell proliferation and malignancy and inhibit cell death (Bos, 1989; Rodenhuis, 1992; Krasilnikov, 2000; Chang et al., 2003) . Several lines of evidence have suggested cross-talk between oncogenic signal transduction and chemoresistance: drug resistance was induced or enhanced upon expression of Ras (Burt et al., 1988; Sklar, 1988; Kopnin et al., 1995; Di Simone et al., 1997; Jin et al., 2003) and c-erbB-2/neu oncogenes (Yu et al., 1996; Knuefermann et al., 2003) . Activation of Ras signalling pathways is associated with the upregulation of target genes involved in drug transport (Chin et al., 1992; Zuber et al., 2000) . Drug treatment may downregulate or activate signalling kinases, respectively (Nakashio et al., 2002; Zhao et al., 2004) . Most importantly for the issue of therapy, enhanced sensitivity to drug treatment was observed in the presence of signalling inhibitors. PI3K inhibition was particularly effective sensitizing pancreatic adenocarcinoma cells (Ng et al., 2000) , ovarian cancer cell lines (Ding et al., 2001; Hu et al., 2002) , breast cancer cells (Clark et al., 2002; Jin et al., 2003) , hormone-refractory prostate cancer cells (Lee et al., 2004) , metastatic colon cancer cells (Wang et al., 2002) and lung cancer cells (Nakashio et al., 2000; Brognard et al., 2001) . Similar effects have been reported for MAPK inhibition (Ding et al., 2001; Jin et al., 2003) .
Up to date, there is limited information about the mechanisms of how signalling pathways control drugmediated apoptosis as well as resistance to drug-induced cell death (Guise et al., 2001) . In the present study, we investigated the effects of inhibiting PI3K and MAPK pathways in the colon cancer cell line HT29 and its doxorubicin-resistant derivative HT29RDB. The anthracycline antibiotic doxorubicin is widely used for treating solid tumors, lymphomas and leukemias. The interaction of doxorubicin with the DNA-topoisomerase II complex is likely to be the primary mechanism resulting in growth arrest or cell death, but toxicity mediated by free radicals and DNA cross-linking may also play a role at high drug levels (Gewirtz, 1999) . We found that the PI3K inhibitor LY294002 (Vlahos et al., 1994) increases drug accumulation, activates caspases 9 and 3, regardless of MRP1 expression in doxorubicin-resistant HT29 colon cancer cells.
Results

LY294002 treatment inhibits cell growth and AKT phosphorylation
The sensitivity of HT29RDB cells towards doxorubicin increased up to threefold upon treatment with the PI3K inhibitor LY294002 at 20 mM, whereas no change was observed in the parental cell line (Figure 1a ). LY294002 treatment also induced resensitization of HT29RDB cells to cisplatin, topotecan and mitoxantrone. Cell viability decreased to 8479% (Po0.05), 7175% (Po0.01), and 68711% (Po0.05), respectively. Sensitivity to 5-fluorouracil and etoposide was not affected. The MEK1/2 inhibitors PD98059 and U0126 did not cause resensitization of HT29RDB cells to doxorubicin. However, both inhibitors caused cell growth inhibition in parental as well as in resistant cells (Figure 1b) .
AKT phosphorylation was reduced in HT29RDB cells after incubation with LY294002 ( Figure 1c) . Doxorubicin was shown to induce cell cycle checkpoints in S and G2 through Cdc25A degradation mediated by the checkpoint kinase 1 (Chk1) protein . To find out if the DNA damage pathway was activated in HT29RDB cells following LY294002 treatment, we analysed the expression of Chk1. At equal intracellular doxorubicin concentrations, the levels of phosphorylated Chk1 were similar in the presence or absence of LY294002 indicating that the DNA damage pathway is equally activated upon treatment with doxorubicin regardless of the presence of LY294002 (Figure 1d ).
Apoptosis induction in HT29RDB cells cotreated with doxorubicin and LY294002
Massive cell death occurred in cells cotreated with the PI3K inhibitor and doxorubicin (Figure 2a) . Early apoptosis was indicated in cells cotreated with 20 mM of LY294002 and doxorubicin by an increase of annexin-V staining (Figure 2b ). The figure shows annexin-V versus propidium iodide (PI) staining after 48 h of treatment. The upward shift in PI-staining (FL3 channel) observed upon treatment with 1 mg/ml of doxorubicin is due to inherent drug fluorescence, which is also detected in the PI channel.
The mechanism of apoptosis is remarkably conserved across species and is mediated by sequential activation of initiator and effector caspases (Kim, 2005) . One possible mechanism by which LY294002 induces apoptosis is by activation of caspase activity. We determined the activity of caspases 3 and 9 after 1 to 4 days of incubation with 20 mM LY294002 and 0, 0.25 and 1.0 mg/ ml of doxorubicin, respectively. LY294002 both accelerated and boosted caspase activation. The profile of caspase3 and 9 activity time courses was similar with a maximum activity after 72 h in presence of inhibitor (Figure 3a) . Caspase cleavage was examined by Western blot as shown in Figure 3b . HT29RDB cells treated with LY294002 had increased levels of caspases 9, 3 and their respective cleaved products. When cells were cotreated with doxorubicin, a synergistic effect in caspase cleavage was observed. These results demonstrate that the initiator caspase 9 and effector caspase 3 are involved in mediating apoptosis upon cotreatment of HT29RDB cells with LY294002 and doxorubicin. We found only partial processing of caspase 8 in the presence of 1 mg/ml doxorubicin ( Figure 3c ) supporting previous findings on activation of caspases by cytostatic drugs and the PI3K-inhibitor LY294002 (Kaushal et al., 2001; Wang et al., 2002; Mizutani et al., 2005) .
MRP1 expression and activity in resistant HT29cells
MRP1 overexpression in HT29RDB cells was detected in various cDNA array analyses Kok et al., 2000; Gyo¨rffy et al., 2005) . To elucidate the mechanism of resensitization to doxorubicin we analysed the effects of LY294002 on MRP1 protein content and intracellular distribution by confocal immunofluorescence microscopy. MRP1 was localized at the cytoplasmic membrane of HT29RDB cells in the presence (Figure 4a ) as well as the absence of doxorubicin (not shown). In the parental cells HT29PAR, no MRP1 expression was detectable, even after a 24 h doxorubicin induction. LY294002 treatment neither affected the expression nor the distribution of MRP1 (Figure 4a) .
We determined the functional activity of the drug transporter MRP1 in HT29PAR and HT29RDB cells by assessing the effect of drug transporter inhibitors on doxorubicin accumulation. In HT29RDB cells, doxorubicin accumulation reached about 50% of the level obtained in HT29PAR cells (Figure 4b ). The MRP1 inhibitors MK-571 and genistein raised the doxorubicin accumulation approximately twofold to the levels as in the sensitive parental cells. A similar increase in drug accumulation did not occur in HT29PAR, indicating that MRP1 is functionally active in HT29RDB cells ( Figure 4b ).
Intracellular distribution of doxorubicin Doxorubicin containing vesicle formation is a characteristic of HT29RDB cells and presents a mechanism for
Sensitization of MRP1-mediated multidrug resistance R Abdul-Ghani et al the export of the cytostatic drug out of the cell. We hypothesized whether LY294002 would alter the intracellular vesicle formation, but could not find any difference when cells were incubated at intracellular equivalent drug concentration and observed in vivo with confocal microscopy ( Figure 4c ). The figure shows clearly that in the presence of LY294002 more doxorubicin accumulates in the cells. Flow cytometric analysis of HT29RDB cells after staining with Annexin-V-FLUOS and propidium iodide as described in Materials and methods HT29RDB cells were exposed to 20 mM LY294002 (LY20) and doxorubicin 1.0 mg/ml for 2 days. The arrow indicates apoptotic cells while the circle region is the shift due to doxorubicin accumulation.
Sensitization of MRP1-mediated multidrug resistance R Abdul-Ghani et al raise intracellular drug levels in a similar fashion. Indeed, when the PI3K-inhibitor was given to the cells, intracellular doxorubicin content increased in a dosedependent manner (Figure 5a ). Neither DMSO nor the PI3K inhibitor wortmannin had any effect on doxorubicin accumulation. Increased drug accumulation was detected as soon as several minutes after drug treatment and was maintained up to 4 days. This suggested that LY294002 inhibited doxorubicin export. So we measured doxorubicin export as the difference between doxorubicin content after 30 min of exposure to 1 mg/ml of doxorubicin and LY294002, and the doxorubicin content following a 30 min release period in the presence of inhibitor alone. Drug export was inhibited by LY294002 in a dose-dependent manner ( Figure 5b ). Next, we investigated the kinetics of drug export in the presence of LY294002. Double reciprocal plot of initial velocity of intracellular doxorubicin accumulation versus concentration in medium at different inhibitor concentrations showed that LY294002 acts as a competitive inhibitor of doxorubicin export (Figure 5c ). The kinetics of drug accumulation resembles a classical competitive inhibition, where 1/V max is not affected. The intercept on the y-axis of the double reciprocal plot of 1/V o versus 1/[S] is the same in the presence and the absence of inhibitor, because a competitive inhibitor does not alter V max (Berg et al., 2002) .
Discussion
Here, we show that the PI3K inhibitor LY294002 sensitizes drug-resistant HT29RDB colon carcinoma cells to doxorubicin-induced apoptosis. Sensitization was not restricted to doxorubicin, but was also observed in cells treated with cytotoxic drugs commonly used in cancer treatment such as cisplatin, topotecan and mitoxantrone. Several mechanisms may be implicated in LY294002/ doxorubicin-mediated cell death. Since PI3K and its lipid products have been implicated in vesicular trafficking (Vanhaesebroeck et al., 1996) , we hypothesized that LY294002 treatment might interfere with the intracellular trafficking of doxorubicin. However, analysis of the intracellular localization of doxorubicin in living cells by confocal microscopy did not reveal any alterations in vesicle formation in the presence of the PI3K-inhibitor. However, an increase in doxorubicin accumulation was detected in HT29RDB treated with LY294002. Another possible mechanism involves the deregulation of the G2/M cell cycle checkpoint kinase Chk1, which is activated after DNA damage induced by irradiation and topoisomerase inhibitors. Chk1 phosphorylates and inactivates the Cdc2 activating phosphatase Cdc25C. This in turn inactivates Cdc2, which leads to G2/M arrest Chen and Sanchez, 2004 ). Inhibition of Chk1 was shown to sensitize tumor Sensitization of MRP1-mediated multidrug resistance R Abdul-Ghani et al cells to doxorubicin and camptothecin . In doxorubicin-treated HT29RDB cells, LY294002 did not increase Chk1 phosphorylation levels. Thus, the sensitization mediated by PI3K-inhibition is not due to alterations in the DNA damage pathway activated by doxorubicin. In advanced prostate carcinoma, the PI3K pathway controls chemoresistance to doxorubicin and paclitaxel through upregulation of multidrug resistance protein 1 (MRP1) at the RNA and protein level. Silencing of MRP1 expression by RNA interference rendered cultured prostate cancer cells susceptible to these drugs (Lee et al., 2004) . The MRP1 protein is differentially expressed in HT29RDB cells, however, LY294002 treatment did not upregulate MRP1 levels, therefore, we excluded the possibility that LY294002 exerts its effects by affecting the drug transporter MRP1 expression in HT29RDB cells. The drug transporter (MRP1) is functionally active in HT29RDB cells, since the classical MRP1 modulators MK571, genistein and indomethacin render them susceptible to cell killing in the presence of doxorubicin. This raised the question whether the PI3K inhibitor LY294002 would affect the elimination (efflux) of the drug in a similar manner as the MRP1 inhibitors. Two lines of evidence had suggested that LY294002 might specifically affect the transporter function of MRP1: doxorubicin was accumulated in HT29RDB cells to a large extent when cotreated with LY294002. 
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Wortmannin, a PI3K inhibitor structurally different from LY294002 (Walker et al., 2000) , neither caused sensitization of HT29RDB cells nor did it affect drug accumulation. LY294002 was designed as a synthetic PI3K inhibitor based on the quercetin, a naturally occurring flavonoid that inhibits a broad range of protein kinases (Srivastava, 1985; Agullo et al., 1997) . Quercetin and other flavonoids inhibit GS-X transporter activity of MRP1 and MRP2 by interaction with the ATP-binding domains (van Zanden et al., 2004) . However, LY294002 does not completely meet the structural requirements for a highly efficient flavonoid-mediated inhibition of the GS-X pump. Although the LY294002 molecule exhibits a planar structure due to a C2-C3 double bond, it lacks hydroxyl groups. We determined the doxorubicin efflux in HT29RDB cells in the presence and absence of LY294002. The efflux inhibition kinetics indicate that LY294002 acts as a competitive inhibitor of the transporter mediating drug efflux. This suggested that the PI3K inhibitor LY294002, but not wortmannin interacts with the drug/substrate-binding site of the MRP1 protein, thereby blocking doxorubicin efflux and inducing the apoptotic response. When applied as a therapeutic agent, LY294002 exhibited selective toxicity to normal cells in the skin. Lowering the total dose of the drug decreased the toxicity (Hu et al., 2002) . Thus, the function of LY294002 as a drug efflux inhibitor may be utilized for applying combination therapy at low LY294002 doses. Cancer cells overexpressing PI3K or PTEN deletion/mutation may be more susceptible to combination therapy. In these cases, LY294002 may have a dual function as a drug efflux inhibitor and by inhibiting the growth/survival PI3K pathway.
Recently, it was reported that the anticancer action of doxorubicin involves the generation of hydrogen peroxide succeeded by an increase in mitochondrial membrane potential and caspase 3 activation (Mizutani et al., 2005) . PI3K-inhibition by LY294002 boosted both the expression and activity of caspase 3 and its upstream caspase 9, suggesting that delayed efflux accelerated the onset of doxorubicin-mediated apoptosis. However, the overall extent of cell killing is not determined by accelerating the induction of apoptosis (Han et al., 1997; Gewirtz, 1999) . Rather, the massive apoptotic cell death observed in cotreated cells may be explained by enhanced caspase activity.
Previous studies have shown that the PI3K/AKT and MAPK pathways may play an equally important role in determining cell death induced by DNA damaging agents (Wang et al., 2000; Liu et al., 2001) .The inhibition of the MAPK pathway did not affect the resistance phenotype of HT29RDB cells. This is in agreement with the study by Zhao et al. (2004) showing that the MAPK pathway is not involved in doxorubicininduced apoptosis of lung adenocarcinoma cells (Zhao et al., 2004) . The effects of various cytotoxic agents may vary considerably depending on the cell type and the signalling pathway activity (Wang et al., 2000; Guise et al., 2001; Liu et al., 2001) . Assessing the status of oncogenic signalling in cancer cells prior to Sensitization of MRP1-mediated multidrug resistance R Abdul-Ghani et al therapy is likely to be a crucial prerequisite for therapeutic efficacy.
Materials and methods
Cell lines
The human colon carcinoma cell line (HT29PAR) and its drug resistant counterpart (HT29RDB) were established in our laboratory as described previously (Chen et al., 1987) . Cells were grown in Leibowitz-15 (L-15) medium containing 10% fetal bovine serum. The medium of the resistant cell line HT29RDB contained additionally 0.125 mg/ml doxorubicin (Farmitalia Carlo Erba, Freiburg, Germany).
Cell proliferation assay Cellular viability and proliferation were measured using the XTT Cell Proliferation kit as described in the manufacturer's instructions (Roche, Mannheim, Germany) (Roehm et al., 1991) . A total of 2000 cells were grown in 96-well plates and after 24 h the cytotoxic drug was added in a dilution series in triplicate wells. Cell viability was measured after 96 h of cotreatment with the inhibitors LY294002, PD98059 or UO126 (Alexis; Gru¨nberg, Germany). To determine the IC 50 -value, the absorbance difference of control cells without drug was set to be 100% viability. Nonlinear regression was performed for XTT assay-based growth/viability measurements obtained in at least three experiments.
Sensitization of HT29RDB cells to various drugs
The resensitization effect of LY294002 treatment on HT29RDB cells was tested for six different drugs with the corresponding concentrations: doxorubicin 0.5 mg/ml (Farmitalia Carlo Erba, Freiburg, Germany), 5-fluorouracil 5 mg/ml (Gry-Pharma, Germany), cisplatin 5 mg/ml (Gry-Pharma), etoposide 1.4 mg/ml (Gry-Pharma), mitoxantrone 0.2 mg/ml (Wyeth-Lederle) and topotecan 0.01 mg/ml (Glaxo Smith Kline, Germany). In all, 400 cells were seeded in 96-well plates. After 1 week the number of cells was determined in six wells and defined as baseline. The treatment with LY294002 was performed simultaneously and the cell chemosensitivity was assessed after 48 h by the sulforhodamine B assay (Skehan et al., 1990) .
Preparation of protein extracts
For Western analysis of total Akt levels, serine 473-phosphoAkt (pAkt) levels, and caspase8 levels, cells were harvested by SDS Sample Buffer (62.5 mM Tris-HCl, pH 6.8; 2% w/v SDS; 10% glycerol; 50 mM DTT; 0.01% w/v bromophenol blue). Lysates for caspases 3 and 9 analysis were prepared by CHAPS Cell Extract Buffer, whereas lysates for Chk1 analysis were prepared by lysis Buffer (10 mM Tris-HCl, pH 7.4; 150 mM NaCl; 5 mM EDTA; 8% glycerol; 1% Triton; 0.15 SDS; 0.5% Deoxycholate; 1 mM Na-orthovanadate; 10 mM NaF; 1 mM PMSF; 1 Â Complete Protease Inhibitor Cocktail (Roche, Mannheim, Germany)). All lysates were incubated 10 min at 901C and centrifuged 5 min at 14 000 r.p.m., 41C before determining protein concentration by Amido Black (BIO-RAD, CA, USA).
Western blot analysis
Phospho-Akt (Ser473), Akt, cleaved caspase 3 (Asp175), cleaved caspase 9 (Asp330), Phospho-Chk1 (Ser345) and caspase 8 (1C12) antibodies were purchased from (Cell Signalling, Technology, Beverly, MA, USA). All these antibodies were diluted 1:1000. b-actin (Chemicon, Temecula, CA, USA) was diluted 1:5000. Chk1 antibody (Santa Cruz Biotechnology, CA, USA) was diluted 1:1000. Mouse and Rabbit peroxidase-conjugated secondary antibodies were from (Dianova, Germany) and diluted 1:10 000. Proteins were subjected to electrophoresis on SDS-polyacrylamide gels. For semi-dry immunoblotting on nitrocellulose membranes, standard procedures were used. Membranes were blocked in 5% low fat milk/TBST, then incubated overnight at 41C with the primary antibody in 5% BSA/TBST, with the exception of b-actin antibody that was incubated for 1 h at room temperature. After three TBST washes the membranes were incubated for 1 h with the secondary antibody in 5% BSA/TBST. Western blots were developed with the ECL TM system (Amersham Pharmacia, Buckingshamshire, UK).
Annexin V staining
Resistant cells HT29RDB were grown in six-well plates and incubated with the desired concentrations of doxorubicin and PI3K inhibitor LY294002 (Alexis; Gru¨nberg, Germany). After 48 h, cells were trypsinized and washed once with PBS. Cells were resuspended in 100 ml of incubation buffer (10 mM Hepes/ NaOH, pH 7.4; 140 mM NaCl; 5 mM CaCl 2 ) containing Annexin-V-Fluos and propidium iodide and incubated for 15 min on ice as recommended in the manufacturer's protocol (Roche diagnostics GmbH). Incubation buffer, 400 ml, was added to the cells shortly before measuring them on a flow cytometer using 488 nm excitation and a 515 nm bandpass filter for fluorescein detection and a filter >600 nm for propidium iodide detection.
Caspase activity
Caspase activity was measured after induction of apoptosis with the ApoAlert Caspase Assay Plates (BD Biosciences, Clontech, USA) following the manufacturer's protocol. Briefly, cells were treated with doxorubicin, LY294002 or DMSO and harvested at different time points.
Whole cell lysates of 20 000 cells were incubated with the fluorogenic dye 7-amino-4-methyl coumarin-bound caspase short peptide substrates that were immobilized in 96-well plates (Caspase profiling assay plates) and then incubated at 371C for 2 h. A CytoFlour II Flourescence Plate Reader set to 380 nm excitation and 460 nm emission was used for fluoroscence measurements.
Fluorescence and immunofluorescence microscopy For immunofluorescence microscopy HT29PAR and HT29RDB cells were incubated in the presence or the absence of 0.25 mg/ml doxorubicin and 20 mm LY294002 for 24 h. Then cells were washed twice with PBS and fixed in acetone:methanol (1:1, 10 min, À201C). Cells were blocked in 1.5% horse serum/PBS for 30 min at room temperature, then incubated with MRP1m6 (MONOSAN) primary antibody (1:10 in 1.5% horse serum/PBS, 60 min, at room temperature) in a humidified chamber. After two washes with PBS cells were incubated with mouse fluorescein-labelled secondary antibody (Dianova, Germany) (1:100 in 1.5% horse serum/PBS, at room temperature, protected from light) and 0.1 mg/ml DAPI. The slides were washed twice with PBS, then covered with Dabco. Confocal laser scanning microscopy was performed at 488 nm and at 568 nm for MRP1 and DAPI detection, respectively.
For intracellular localization of doxorubicin, resistant cells were grown in four-well glass slide borsilicate chambered-slide system (Nalge Nunc Int.) and incubated with doxorubicin and LY294002 or DMSO for 48 h. Doxorubicin intracellular localization was detected by confocal microscopy on living cells.
MRP1 functional activity
The functional activity of MRP1 was determined by assessing the effect of MRP1 inhibitors on doxorubicin accumulation as described previously (Plasschaert et al., 2003) . The inhibitor genistein was obtained from Sigma Aldrich Chemie-GmbH while MK-571 was obtained from Biomol (Gekeler et al., 1995; van Zuylen et al., 2000) . In brief, cells (5 Â 10 4 ) were preincubated with 30 mM of the inhibitor MK571 or genistein for 20 min at 371C, 5% CO 2 . Doxorubicin and LY294002 were added in the concentrations of 1.0 mg/ml and 20 mM, respectively. The cells were incubated for 60 min at 371C, 5% CO 2 and agitated every 10 min. Pelleted cells (5 min, 2000 r.p.m., 41C) were resuspended in PBS shortly before measuring them on a flow cytometer using FL-2 for doxorubicin detection. The geometrical mean of the doxorubicin cellular distribution was recorded (WinMDI version 2.8).
Intracellular drug accumulation kinetics
Sensitive and resistant HT29 cells were resuspended in L-15 medium and incubated at 371C with the desired concentrations of doxorubicin and LY294002 at a concentration of 5 Â 10 5 cells/ml in a CO 2 air incubator. After 10, 20, 30 and 40 min of incubation samples were collected. Pelleted cells (5 min, 2000 r.p.m., 41C) were resuspended in PBS shortly before measuring them on a flow cytometer using FL-2 for doxorubicin detection. The geometrical mean of the doxorubicin intracellular distribution was recorded (WinMDI version 2.8). The initial velocity (V 0 ) of the accumulation reaction was measured for each doxorubicin (substrate) and LY294002 (inhibitor) concentration as the increase of intracellular doxorubicin content versus time. Line weaver-Burk graphs were plotted using reciprocal data for the intracellular doxorubicin concentration and initial velocity.
Statistical analysis
Results are expressed as mean7s.d. Statistical analysis was performed using the Student's t-test. Po0.05 was considered statistically significant.
